Segmental Transcatheter Arterial Chemoembolization Treatment in Patients with Cirrhosis and Inoperable Hepatocellular Carcinomas

摘要: PURPOSE To establish whether segmental transcatheter arterial chemoembolization (TACE) treatment may improve the rates of survival in patients with compensated cirrhosis and inoperable hepatocellular carcinoma (HCC). MATERIALS AND METHODS Fifty-six HCC were treated TACE. One hundred forty treatments (mean, 2.5 per patient; 30–60 mg Epirubicin, 4–10 mL Lipiodol, Gelfoam particles) administered. RESULTS During 69-month study, 25 (45%) died tumor progression, 12 (21%) liver failure, nine (16%) gastrointestinal hemorrhage, three (5%) other causes; seven (13%) are still alive. The 3-year rate was 32%. Intention-to-treat analysis determined that Child-Pugh class A disease ( n = 44; 79%) or a single 21; 37%) had higher than those B 12; 21%; P 35; 63%; 41) who more one course TACE procedure 15; 16) 56%. This result similar to 50% untreated historic controls characteristics. CONCLUSION did not appear use therapy.